mRNA Display Identifies Potent, Paralog-Selective Peptidic Ligands for ARID1B.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
24 Apr 2024
Historique:
medline: 24 4 2024
pubmed: 24 4 2024
entrez: 24 4 2024
Statut: aheadofprint

Résumé

The ARID1A and ARID1B subunits are mutually exclusive components of the BAF variant of SWI/SNF chromatin remodeling complexes. Loss of function mutations in ARID1A are frequently observed in various cancers, resulting in a dependency on the paralog ARID1B for cancer cell proliferation. However, ARID1B has never been targeted directly, and the high degree of sequence similarity to ARID1A poses a challenge for the development of selective binders. In this study, we used mRNA display to identify peptidic ligands that bind with nanomolar affinities to ARID1B and showed high selectivity over ARID1A. Using orthogonal biochemical, biophysical, and chemical biology tools, we demonstrate that the peptides engage two different binding pockets, one of which directly involves an ARID1B-exclusive cysteine that could allow covalent targeting by small molecules. Our findings impart the first evidence of the ligandability of ARID1B, provide valuable tools for drug discovery, and suggest opportunities for the development of selective molecules to exploit the synthetic lethal relationship between ARID1A and ARID1B in cancer.

Identifiants

pubmed: 38655884
doi: 10.1021/acschembio.4c00083
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Gregor S Cremosnik (GS)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Yannick Mesrouze (Y)

Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Patrik Zueger (P)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

David Furkert (D)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Frédéric Grandjean (F)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Dayana Argoti (D)

Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.

Fanny Mermet-Meillon (F)

Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Matthias R Bauer (MR)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Scott Brittain (S)

Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.

Phuong Rogemoser (P)

Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.

Winnie Yang (W)

Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.

Jerome Giovannoni (J)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Lynn McGregor (L)

Discovery Sciences, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.

Jenny Tang (J)

Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.

Mark Knapp (M)

Global Discovery Chemistry, Novartis Biomedical Research, Emeryville, California 94608, United States.

Sandra Holzinger (S)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Sylvia Buhr (S)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Lionel Muller (L)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Lukas Leder (L)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Lili Xie (L)

Discovery Sciences, Novartis Biomedical Research, Emeryville, California 94608, United States.

Cesar Fernandez (C)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Cristina Nieto-Oberhuber (C)

Global Discovery Chemistry, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Patrick Chène (P)

Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Giorgio G Galli (GG)

Disease area Oncology, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Fabian Sesterhenn (F)

Discovery Sciences, Novartis Biomedical Research, CH-4056 Basel, Switzerland.

Classifications MeSH